Recent efforts to identify anti-angiogenic compounds from natural products based on their effects on other essential tumorigenic pathways [68], and development of human fibulin-3 variant with dual antivascular function [69] beside other tumor-suppression effects in brain tumor model [70], are promising new directions in the evolution of cancer therapy. This evidence concerns the gene EFEMP1 and cancer.